Filtered By:
Nutrition: Sodium
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 1017 results found since Jan 2013.
Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials
ConclusionsSodium-glucose cotransporter inhibitors significantly reduced major adverse cardiovascular events, including hospitalization and all-cause mortality in patients with or without established atherosclerotic cardiovascular disease. We observed a beneficial trend in patients with heart failure with preserved ejection fraction, and no benefi ts in patients with stroke or myocardial infarction.
Source: American Journal of Cardiovascular Drugs - December 27, 2022 Category: Cardiology Source Type: research
Disparities in Adoption of New Diabetic Therapies with Cardiovascular Benefits
Cardiovascular disease remains the most common cause of death among patients with diabetes [1 –3]. Two recently approved classes of medications for Type 2 diabetes mellitus (T2DM) reduce the risk of cardiovascular events. Glucagon-like peptide-1 agonists (GLP1RA) reduce death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke in patients T2DM[5–10]. Sodium-gl ucose co-transporter 2 inhibitors (SGLT2i) reduce heart failure events by 27% to 39% and decrease the frequency of worsening renal disease by 39% compared to placebo in patients with T2DM.
Source: Diabetes Research and Clinical Practice - December 26, 2022 Category: Endocrinology Authors: Elena C. Vasti, Marina Basina, Jamie Calma, David J. Maron, Fatima Rodriguez, Alexander T. Sandhu Source Type: research
Pollutants In Your Salt!?
Your doctor, the media, and the medical establishment continue to warn that flavoring your food with salt will kill you. They link sodium consumption to a higher risk of high blood pressure, stroke – and of course, heart disease.
As usual, the powers that be are missing the real picture…
You see, salt has been part of human life for thousands of years – long before these chronic diseases became as common as they are today.
Humans started adding salt to their food for more than 5,000 years. It was the most effective way to preserve food.
Some historians even go as far as to credit salt for the development of human civ...
Source: Al Sears, MD Natural Remedies - December 23, 2022 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Health Source Type: news
EPO has multiple positive effects on astrocytes in an experimental model of ischemia
Brain Res. 2022 Dec 19:148207. doi: 10.1016/j.brainres.2022.148207. Online ahead of print.ABSTRACTErythropoietin (EPO) has neuroprotective effects in central nervous system injury models. In clinical trials EPO has shown beneficial effects in traumatic brain injury (TBI) as well as in ischemic stroke. We have previously shown that EPO has short-term effects on astrocyte glutamatergic signalling in vitro and that administration of EPO after experimental TBI decreases early cytotoxic brain edema and preserves structural and functional properties of the blood-brain barrier. These effects have been attributed to preserved or r...
Source: Brain Research - December 22, 2022 Category: Neurology Authors: Jonas Blixt Yutong Song Michael Wanecek Eli Gunnarson Source Type: research
Dietary evaluation of sodium intake in patients with chronic kidney disease
CONCLUSION: the non-correlation between sodium obtained by 24-hour urinary excretion and dietary intake demonstrates the fragility of the estimation of sodium excretion through the dietary survey.PMID:36537325 | DOI:10.20960/nh.04255
Source: Nutricion Hospitalaria - December 20, 2022 Category: Nutrition Authors: Elisangela Milhomem Santos La ísa Cristina Camões Cunha Raimunda Sheyla Carneiro Dias Maria C élia Cruz Diniz Dyego Jos é Araujo Brito Thaisa Cristina Sousa Teixeira Alcione Miranda Dos Santos Ana Karina Teixeira da Cunha Fran ça Source Type: research
Why Are Cardiologists Not Prescribing the New Diabetes Medications?
Randomized clinical trials and guidelines from multiple societies have established significant cardiovascular (CV) outcome benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D). Among patients with T2D, those with known CV disease and those at high risk who are receiving metformin have lower risks of death, myocardial infarction, and stroke if they are treated with GLP-1RAs, and those treated with SGLT2is have reduced risks of hospital admission for heart failure, CV mortality, and all-cause mortality.
Source: The American Journal of Cardiology - December 14, 2022 Category: Cardiology Authors: Lloyd W. Klein Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
Abstract Purpose of ReviewThis forward-looking review summarizes existing evidence from cardiovascular outcome trials on cardiometabolic risk-reduction in type 2 diabetes (T2DM) management, with attention to updating and personalizing recommendations from recent diabetes practice guidelines issued by cardiology societies.Recent FindingsT2DM management has shifted towards cardiometabolic outcome improvement rather than purely glycemic control. According to large clinical trials, sodium-glucose cotransporter-2 inhibitors showed robust results in reducing heart failure (HF) hospitalization and chronic kidney disease (CKD) p...
Source: Current Atherosclerosis Reports - November 24, 2022 Category: Cardiology Source Type: research
NaF-PET shows bone formation in psoriatic arthritis patients
F-18 sodium fluoride (NaF) PET/CT may be a valuable tool for imaging patient...Read more on AuntMinnie.comRelated Reading:
NaF-PET reveals aortic wall injuries
NaF-PET scans reveal plaque -- and possible risk of stroke
NaF-PET/CT does well in detecting prostate metastases
NaF-PET/CT rarely finds prostate cancer bone metastases
AI algorithm can classify bone lesions on PET/CT images
Source: AuntMinnie.com Headlines - November 18, 2022 Category: Radiology Source Type: news
Modulators of ASIC1a and its potential as a therapeutic target for age-related diseases
Ageing Res Rev. 2022 Nov 9:101785. doi: 10.1016/j.arr.2022.101785. Online ahead of print.ABSTRACTAge-related diseases have become more common with the advancing age of the worldwide population. Such diseases involve multiple organs, with tissue degeneration and cellular apoptosis. To date, there is a general lack of effective drugs for treatment of most age-related diseases and there is therefore an urgent need to identify novel drug targets for improved treatment. Acid-sensing ion channel 1a (ASIC1a) is a degenerin/epithelial sodium channel family member, which is activated in an acidic environment to regulate pathophysio...
Source: Ageing Research Reviews - November 12, 2022 Category: Genetics & Stem Cells Authors: Ren-Peng Zhou Hong-Yu Liang Wei-Rong Hu Jie Ding Shu-Fang Li Yong Chen Ying-Jie Zhao Chao Lu Fei-Hu Chen Wei Hu Source Type: research
Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
J Clin Med. 2022 Nov 4;11(21):6544. doi: 10.3390/jcm11216544.ABSTRACTChronic hyperglycemia induces pathophysiologic pathways with negative effects on the metabolism of most substrates as well as lipids and lipoproteins, and thereby induces dyslipidemia. Thus, the diabetic milieu is commonly accompanied by different levels of atherogenic dyslipidemia, which is per se a major risk factor for subsequent complications such as atherosclerosis, coronary heart disease, acute myocardial infarction, ischemic stroke, and nephropathy. Therefore, readjusting lipid metabolism in the diabetic milieu is a major goal for preventing dyslip...
Source: Atherosclerosis - November 11, 2022 Category: Cardiology Authors: Habib Yaribeygi Mina Maleki Željko Reiner Tannaz Jamialahmadi Amirhossein Sahebkar Source Type: research
Kids and sodium: Serious risks, alarming realities
When it comes to sodium intake among adults, the general consensus is that high consumption will increase risk of hypertension and stroke. According to the 2020 –2025 Dietary Guideline for Americans, 45% of people 18 and older are living with hypertension. Hypertension is a preventable risk factor for cardiovascular disease and stroke. Does a high sodium intake pose the same risks for children and adolescents as it does for adults? Children and adolescent s, ages 2–18, develop…
Source: News from Mayo Clinic - November 8, 2022 Category: Databases & Libraries Source Type: news
